Expression of urokinase and urinary trypsin inhibitor in metastatic and non-metastatic murine Lewis lung carcinoma cells

International Journal of Oncology

Volumn 8, Issue 4, 1996, Pages 757-763

  Kobayashi, Hiroshi ^a   Gotoh, Junko ^a   Hirashima, Yasuyuki ^a   Terao, Toshihiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lewis lung carcinoma; Metastasis; Urinary trypsin inhibitor; Urokinase type plasminogen activator

Indexed keywords

MATRIGEL; ULINASTATIN; UROKINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; LEWIS CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029944630     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.8.4.757     Document Type: Article

References (37)

1. Liotta LA, Rao CN and Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 49: 636-649, 1983.
2. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen PI, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985.
3. Ossowski L: In vivo invasion of modified chorioallantoic membrane by tumor cells: The role of cell surface-bound urokinase. J Cell Biol 107: 2437-2445, 1988.
4. Mignatti P, Robbins E and Rifkin DB: Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 47: 489-498, 1986.
5. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC and Miskin R: Effects of inhibitors, of plasminogen activator, serine proteases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48: 3307-3312, 1988.
6. Skriver L, Larsson L-I, Kielberg V, Nielsen LS and Andreasen PB: Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 99: 752-757, 1984.
7. Hearing VJ, Law LW, Corti A, Appella E and Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270-1278, 1988.
8. Ossowski L, Russo-Payne H and Wilson EL: Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274-281, 1991.
9. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Gunzler WA, Janicke F and Graeff H: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 266: 5147-5152, 1991.
10. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52: 3610-3614, 1992.
11. Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F: Autocrine saturation of prouro-kinase receptors on human A431 cells. Cell 45: 675-684, 1986.
12. Hochstrasser K, Schonberger OL, Rossmanith I and Wachter E: Kunitz-type proteinase inhibitors derived by limited proteolysis of inter-α-trypsin inhibitor. Physiol Chem Hoppe-Seyler 362: 1357-1362, 1981.
13. Wachter E, and Hochstrasser K: Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-α-trypsin inhibitor, IV. Physiol Chem Hoppe-Seyler 362: 1351-1355, 1981.
14. Albrecht GJ, Hochstrasser K and Salier J-P: Elastase inhibition of the inter-α-trypsin inhibitor and derived inhibitors of man and cattle. Physiol Chem Hoppe-Seyler 364: 1703-1708, 1983.
15. Reisinger P, Hochstrasser K, Albrecht GJ, Lempart K and Salier J-P: Human inter-α-trypsin inhibitor: Localization of the Kunitz-type domains in the N-terminal part of the molecule and their release by a trypsin-like proteinase. Biol Chem Hoppe-Seyler 366: 479-483, 1985.
16. Balduyck M, Laroui S, Mizon C and Mizon J: A proteoglycan related to the urinary trypsin inhibitor (UTI) links the two heavy chains of inter-α-trypsin inhibitor. Biol Chem Hoppe-Seyler 370: 329-336, 1989.
17. Hochstrasser K, Albrecht GJ, Schonberger OL and Wachter E: Kunitz-type protease inhibitors derived by limited proteolysis of the inter-α-trypsin inhibitor, VIII. Physiol Chem Hoppe-Seyler 370: 1689-1696, 1989.
18. Gebhard W, Hochstrasser K, Fritz H, Enghild J, Pizzo SV and Salvesen G: Structure of inter-α-inhibitor (inter-α-trypsin inhibitor: Current state and proposition of a new terminology. Biol Chem Hoppe-Seyler 371: 13-22, 1990.
19. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa M and Terao T: Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 57: 727-733, 1994.
20. Kobayashi H, Fujie M, Shinohara H, Ohi H, Sugimura M and Terao T: Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. Int J Cancer 57: 378-384, 1994.
21. Kobayashi H, Shinohara H, Ohi H, Sugimura M and Terao T: Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clin Exp Metastasis 12: 117-128, 1994.
22. Kobayashi H, Gotoh J, Fujie M and Terao T: Characterization of the cellular binding site for the urinary trypsin inhibitor. J Biol Chem 269: 20642-20647, 1994.
23. Testa JE: Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloprotease 2. Cancer Res 52: 5597-5603, 1992.
24. Kobayashi H, Gotoh J, Shinohara H, Moniwa N and Terao T: Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 71: 474-480, 1994.
25. Corti A, Nolli ML and Cassani G: Differential detection of single-chain and two-chain urokinase-type plasminogen activator by a new immunoadsorbent-amidolytic assay (IAA). Thromb Haemost 56: 407-410, 1986.
26. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239-3245, 1987.
27. Fidler IJ: Selection of successive tumor lines for metastasis. Nature 242: 148-149, 1973.
28. Brodt P, Reich R, Moroz LA and Chambers AF: Differences in the repertories of basement membrane degrading enzymes in two carcinoma sublines with distinct patterns of site-selective metastasis. Biochim Biophys Acta 1139: 77-83, 1992.
29. Korczak B, Kerbel RS and Dennis J: Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines. Int J Cancer 48: 557-561, 1991.
30. Foekens LA, Schmitt M, van Putten WLJ, Peters HA, Brontenbal M, Janicke F and Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
31. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K and Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
32. Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP and Salvatore M: Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 53: 5445-5454, 1994.
33. Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are studied to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530, 1994.
34. Grondahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR and Dano K: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138: 111-117, 1991.
35. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G and Salvatore M: Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels. Cancer Res 53: 3198-3206, 1993.
36. Pyke C, Graem N, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Brunner N and Dano K: Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915, 1993.
37. Kobayashi H, Hiroshima Y, Gotoh J, Sugino D and Terao T: Urinary trypsin inhibitor, a Kunitz-type protease inhibitor, modulates tumor necrosis factor-stimulated activation and translocation of protein kinase C in U937 cells. J Biol Chem (In press).